CN102802608A - 阿哌沙班的剂型 - Google Patents

阿哌沙班的剂型 Download PDF

Info

Publication number
CN102802608A
CN102802608A CN2010800362888A CN201080036288A CN102802608A CN 102802608 A CN102802608 A CN 102802608A CN 2010800362888 A CN2010800362888 A CN 2010800362888A CN 201080036288 A CN201080036288 A CN 201080036288A CN 102802608 A CN102802608 A CN 102802608A
Authority
CN
China
Prior art keywords
apixaban
dosage form
piperazine
drug
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800362888A
Other languages
English (en)
Chinese (zh)
Inventor
R.G.诺斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Pfizer Inc
Original Assignee
Bristol Myers Squibb Co
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Pfizer Inc filed Critical Bristol Myers Squibb Co
Publication of CN102802608A publication Critical patent/CN102802608A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800362888A 2009-06-16 2010-06-15 阿哌沙班的剂型 Pending CN102802608A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18744209P 2009-06-16 2009-06-16
US61/187,442 2009-06-16
PCT/US2010/038660 WO2010147978A1 (en) 2009-06-16 2010-06-15 Dosage forms of apixaban

Publications (1)

Publication Number Publication Date
CN102802608A true CN102802608A (zh) 2012-11-28

Family

ID=42677548

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800362888A Pending CN102802608A (zh) 2009-06-16 2010-06-15 阿哌沙班的剂型

Country Status (24)

Country Link
US (4) US20120087978A1 (https=)
EP (2) EP3520776A1 (https=)
JP (1) JP5775071B2 (https=)
KR (1) KR20120029428A (https=)
CN (1) CN102802608A (https=)
AU (1) AU2010260208B2 (https=)
BR (1) BRPI1010739A2 (https=)
CA (1) CA2765413A1 (https=)
CY (1) CY1122685T1 (https=)
DK (1) DK2442791T3 (https=)
ES (1) ES2769357T3 (https=)
HR (1) HRP20200297T1 (https=)
HU (1) HUE048542T2 (https=)
IL (1) IL216421A0 (https=)
LT (1) LT2442791T (https=)
MX (1) MX2011013080A (https=)
PL (1) PL2442791T3 (https=)
PT (1) PT2442791T (https=)
RU (1) RU2012101214A (https=)
SG (1) SG176785A1 (https=)
SI (1) SI2442791T1 (https=)
SM (1) SMT202000093T1 (https=)
WO (1) WO2010147978A1 (https=)
ZA (1) ZA201109334B (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104721156A (zh) * 2013-12-18 2015-06-24 山东新时代药业有限公司 一种含利伐沙班的片剂
CN104971355A (zh) * 2014-04-02 2015-10-14 上海现代药物制剂工程研究中心有限公司 含有利伐沙班的组合物及其制备方法
CN106902115A (zh) * 2015-12-22 2017-06-30 江苏万邦生化医药股份有限公司 阿哌沙班在治疗糖尿病足药物中的应用
CN106986868A (zh) * 2016-01-21 2017-07-28 广东东阳光药业有限公司 包含阿哌沙班的共晶体及其制备方法
CN108236604A (zh) * 2018-02-07 2018-07-03 中国药科大学 阿哌沙班柔性脂质体
CN109010273A (zh) * 2018-10-08 2018-12-18 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
CN110037990A (zh) * 2019-04-15 2019-07-23 海正药业(杭州)有限公司 一种阿哌沙班固体无定形分散体的制备工艺
WO2020034989A1 (zh) 2018-08-14 2020-02-20 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN113891705A (zh) * 2019-03-27 2022-01-04 Hlb制药有限责任公司 用于制备负载阿哌沙班的微球的分散相的组合物和由其制备的基于生物相容性聚合物的负载阿哌沙班的微球
JP2022032772A (ja) * 2020-08-14 2022-02-25 日医工株式会社 アピキサバン含有医薬組成物
CN115715770A (zh) * 2021-08-24 2023-02-28 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN06587A (https=) * 2010-02-25 2015-10-23 Bristol Myers Squibb Co
CA2830948A1 (en) * 2011-03-25 2012-10-04 Selecta Biosciences, Inc. Osmotic mediated release synthetic nanocarriers
EP2554159A1 (en) 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
US20150018386A1 (en) * 2012-03-06 2015-01-15 Cadila Healthcare Limited Amorphous form of apixaban, process of preparation and compositions thereof
IN2014MN02245A (https=) * 2012-04-10 2015-10-09 Rubicon Res Private Ltd
US20150272891A1 (en) * 2012-05-24 2015-10-01 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
MY179191A (en) * 2012-09-26 2020-10-30 Pfizer Apixaban liquid formulations
KR20160098508A (ko) * 2013-12-23 2016-08-18 라보라토리오스 델 드라. 에스테브.에스.에이. 경구용 약학 조성물
EP2907507A1 (en) * 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
US20150335586A1 (en) 2014-05-20 2015-11-26 R.P. Scherer Technologies, Llc Capsule dispensing container
JP6359390B2 (ja) * 2014-09-05 2018-07-18 テルモ株式会社 インプラントデバイスおよびインプラントデバイス植え込み具
EP3380083A1 (en) 2015-11-26 2018-10-03 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
WO2017121340A1 (zh) 2016-01-12 2017-07-20 广东东阳光药业有限公司 阿哌沙班固体组合物及其制备方法
US11154558B2 (en) 2016-04-15 2021-10-26 Adams Pharmaceuticals LLC Prevention of atherosclerotic events with direct factor Xa inhibitors
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
EP3826609A4 (en) * 2018-02-21 2022-01-12 Blaesi, Aron H. EXPANDING STRUCTURED DOSAGE FORM
PT3781132T (pt) * 2018-04-16 2024-05-16 Pfizer Formulações de apixabano
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
KR102044676B1 (ko) 2019-03-27 2019-11-14 주식회사 씨트리 생체적합성 고분자 기반 아픽사반 함유 미립구의 제조방법
WO2020219384A1 (en) * 2019-04-26 2020-10-29 Taho Pharmaceuticals Ltd. Apixaban transdermal delivery system and uses thereof
WO2020231791A1 (en) * 2019-05-10 2020-11-19 Fordoz Pharma Corp. Injectable polymer nanoparticle compositions of antithrombotic agents and methods thereof
AU2020348783B2 (en) 2019-09-18 2026-04-16 Bristol-Myers Squibb Company Extended release dosage forms for Tyk2 inhibitors
JP7752487B2 (ja) * 2020-03-24 2025-10-10 日本ジェネリック株式会社 アピキサバン含有固体分散体
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
EP4213813A1 (en) * 2020-09-18 2023-07-26 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
WO2022123074A1 (en) * 2020-12-13 2022-06-16 Dafechem Ltd Liquid apixaban formulation in small dose volume
IL309098A (en) * 2021-06-08 2024-02-01 Taho Pharmaceuticals Ltd Apixaban layer product and its uses
US12213972B2 (en) * 2022-07-27 2025-02-04 Slayback Pharma Llc Stable pharmaceutical compositions of apixaban
WO2024144207A1 (en) * 2022-12-26 2024-07-04 Rexpharmtech Co., Ltd Sustained-release tablet comprising apixaban
AU2024256542A1 (en) * 2023-04-18 2025-10-23 Incyclix Bio, Llc Advantageous human dosage regimens for administration of inx-315
EP4731217A1 (en) * 2023-06-23 2026-04-29 Ronak Patel A gastroretentive composition comprising apixaban

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1027887A2 (en) * 1999-02-10 2000-08-16 Pfizer Products Inc. Matrix controlled release device
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
CN101340933A (zh) * 2005-08-17 2009-01-07 百时美施贵宝公司 具有环糊精的因子xa抑制剂包合配合物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4247498A (en) 1976-08-30 1981-01-27 Akzona Incorporated Methods for making microporous products
US4564488A (en) 1978-07-31 1986-01-14 Akzo Nv Methods for the preparation of porous fibers and membranes
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
US4490431A (en) 1982-11-03 1984-12-25 Akzona Incorporated 0.1 Micron rated polypropylene membrane and method for its preparation
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US5225192A (en) 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6492991B1 (en) 1998-08-28 2002-12-10 Ati International Srl Method and apparatus for controlling compressed Z information in a video graphics system
WO2000001389A1 (en) 1998-07-06 2000-01-13 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2003000295A2 (en) 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
ES2284871T3 (es) * 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
EE200400034A (et) 2001-06-22 2004-06-15 Pfizer Products Inc. Amorfse ravimaine adsorbaatide farmatseutilised kompositsioonid
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20030175346A1 (en) 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
DE60322665D1 (de) * 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1653926A1 (en) 2003-08-04 2006-05-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
GB0417132D0 (en) 2004-07-31 2004-09-01 Koninkl Philips Electronics Nv A shift register circuit
US20060069085A1 (en) 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7396932B2 (en) 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20070259913A1 (en) * 2006-05-04 2007-11-08 David Deitchman Prophylaxis of thromboembolic events in cancer patients
US20090285887A1 (en) 2006-09-12 2009-11-19 Omar Abdelfattah Abu-Baker Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor
EP2090300A4 (en) 2006-11-30 2010-02-10 Takeda Pharmaceutical PREPARATION WITH DELAYED RELEASE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1027887A2 (en) * 1999-02-10 2000-08-16 Pfizer Products Inc. Matrix controlled release device
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
CN101340933A (zh) * 2005-08-17 2009-01-07 百时美施贵宝公司 具有环糊精的因子xa抑制剂包合配合物

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104721156A (zh) * 2013-12-18 2015-06-24 山东新时代药业有限公司 一种含利伐沙班的片剂
CN104971355A (zh) * 2014-04-02 2015-10-14 上海现代药物制剂工程研究中心有限公司 含有利伐沙班的组合物及其制备方法
CN104971355B (zh) * 2014-04-02 2018-04-24 上海现代药物制剂工程研究中心有限公司 含有利伐沙班的组合物及其制备方法
CN106902115A (zh) * 2015-12-22 2017-06-30 江苏万邦生化医药股份有限公司 阿哌沙班在治疗糖尿病足药物中的应用
CN106986868B (zh) * 2016-01-21 2020-04-21 广东东阳光药业有限公司 包含阿哌沙班的共晶体及其制备方法
CN106986868A (zh) * 2016-01-21 2017-07-28 广东东阳光药业有限公司 包含阿哌沙班的共晶体及其制备方法
CN108236604A (zh) * 2018-02-07 2018-07-03 中国药科大学 阿哌沙班柔性脂质体
CN112261935A (zh) * 2018-08-14 2021-01-22 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
WO2020034989A1 (zh) 2018-08-14 2020-02-20 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN109010273A (zh) * 2018-10-08 2018-12-18 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
CN109010273B (zh) * 2018-10-08 2021-03-19 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
CN113891705A (zh) * 2019-03-27 2022-01-04 Hlb制药有限责任公司 用于制备负载阿哌沙班的微球的分散相的组合物和由其制备的基于生物相容性聚合物的负载阿哌沙班的微球
CN113891705B (zh) * 2019-03-27 2024-04-09 Hlb制药有限责任公司 用于制备负载阿哌沙班的微球的分散相的组合物和由其制备的基于生物相容性聚合物的负载阿哌沙班的微球
CN110037990A (zh) * 2019-04-15 2019-07-23 海正药业(杭州)有限公司 一种阿哌沙班固体无定形分散体的制备工艺
CN110037990B (zh) * 2019-04-15 2023-03-28 海正药业(杭州)有限公司 一种阿哌沙班固体无定形分散体的制备工艺
JP2022032772A (ja) * 2020-08-14 2022-02-25 日医工株式会社 アピキサバン含有医薬組成物
JP7520351B2 (ja) 2020-08-14 2024-07-23 日医工株式会社 アピキサバン含有医薬組成物
CN115715770A (zh) * 2021-08-24 2023-02-28 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法
WO2023025195A1 (zh) * 2021-08-24 2023-03-02 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法
CN115715770B (zh) * 2021-08-24 2024-01-26 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法

Also Published As

Publication number Publication date
WO2010147978A1 (en) 2010-12-23
EP2442791B1 (en) 2019-11-27
SI2442791T1 (sl) 2020-03-31
EP3520776A1 (en) 2019-08-07
PT2442791T (pt) 2020-02-06
HRP20200297T1 (hr) 2020-05-29
BRPI1010739A2 (pt) 2016-03-15
HUE048542T2 (hu) 2020-08-28
ES2769357T8 (es) 2020-08-06
US20170202826A1 (en) 2017-07-20
KR20120029428A (ko) 2012-03-26
PL2442791T3 (pl) 2020-05-18
AU2010260208A1 (en) 2011-12-15
ES2769357T3 (es) 2020-06-25
EP2442791A1 (en) 2012-04-25
SMT202000093T1 (it) 2020-03-13
RU2012101214A (ru) 2013-07-27
JP5775071B2 (ja) 2015-09-09
AU2010260208B2 (en) 2014-11-13
CA2765413A1 (en) 2010-12-23
JP2012530141A (ja) 2012-11-29
LT2442791T (lt) 2020-02-25
MX2011013080A (es) 2012-01-20
US20140335178A1 (en) 2014-11-13
ZA201109334B (en) 2014-05-28
US20120087978A1 (en) 2012-04-12
DK2442791T3 (da) 2020-03-02
US20140030330A1 (en) 2014-01-30
CY1122685T1 (el) 2021-03-12
IL216421A0 (en) 2012-02-29
SG176785A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
JP5775071B2 (ja) アピキサバンの製剤形
US7235260B2 (en) Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor
RU2351316C2 (ru) Лекарственные формы с замедленным высвобождением зипразидона
JP5285913B2 (ja) 経口投与できる固体の放出改変型医薬投与形
CN105358535A (zh) 恩杂鲁胺制剂
JP7224337B2 (ja) ３－フルオロ－４－［７－メトキシ－３－メチル－８－（１－メチル－１Ｈ－ピラゾール－４－イル）－２－オキソ－２，３－ジヒドロ－イミダゾ［４，５－ｃ］キノリン－１－イル］－ベンゾニトリル含む医薬製剤
JP2006213713A (ja) コレステリルエステル輸送タンパク質阻害剤およびＨＭＧ−ＣｏＡレダクターゼ阻害剤の剤形
JP2008511609A (ja) 低−溶解性薬物の速放及び徐放を組み合わせた制御放出型投薬形態
HK40012633A (en) Dosage forms of apixaban
HK1164738B (en) Dosage forms of apixaban
HK1164738A (en) Dosage forms of apixaban
HK1117755A (en) Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121128